Hims & Hers is facing battles on multiple fronts as it seeks to maintain its lucrative business in copycat weight loss drugs.
Indiana lawmakers are weighing new guardrails around drug compounding amid warnings that patients are receiving powerful prescription treatments in settings that operate largely outside state ...
The recent withdrawal of Hims & Hers’ GLP-1 pill raises questions about the safety and effectiveness of compounded medications ...
The FDA announced Friday that it intends to restrict the active pharmaceutical ingredients of glucagon-like peptide-1 (GLP-1) receptor agonists used in unapproved compounded drugs that are being ...
Compounded semaglutide and Ozempic are different products. While both may be used in people with type 2 diabetes, Ozempic is approved by the FDA, but compounded semaglutide is not. Compounded drugs ...
The FDA said on Friday it plans to restrict GLP-1 ingredients used in non-approved compounded drugs from companies like Hims & Hers.
Hims & Hers has withdrawn its $49 compounded semaglutide pill after pressure from top U.S. health officials at the FDA and HHS. The company now faces a lawsuit from Novo Nordisk for patent ...
The compounded GLP-1 drug debate isn’t quite over. Weight loss platform Noom launched a full-page print ad in The Wall Street Journal this week, calling on policymakers to create new guidance around ...
OpenLoop, a company providing operational and tech services to telehealth companies, and compounding pharmacy Triad Rx are being sued in a class action for selling oral tirzepatide. | The complaint ...
On Thursday, Hims & Hers Health Inc. (NYSE:HIMS) announced Thursday an expansion of its weight loss specialty by enabling ...
Hims Hers Health announced on Saturday that it will stop offering access to its compounded semaglutide pill following a ...
Add Yahoo as a preferred source to see more of our stories on Google. Lawmakers are considering adding oversight to medical spas that often provide compounded GLP-1 medications at lower prices. (Photo ...